Investigating the effect of methylphenidate on the level of consciousness in loss of consciousness patients due to poisoning
Phase 3
Recruiting
- Conditions
- loss of consciousness.
- Registration Number
- IRCT20220305054196N4
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Age 18 years and above
Informed consent of the legal guardian of the patient to participate in the study
Having decreased consciousness due to poisoning (GCS 13 and below)
Having the ability to move to measure the movement
Exclusion Criteria
History of allergy to methylphenidate
Po intolerance
Unstable vital signs
Pregnancy and lactation in female patients
Receiving a specific antidote (example: Flumazenin, Naloxone, etc.)
Having mental retardation, blindness, deafness
Having a history of brain damage, high blood pressure, ischemic heart disease
Having epilepsy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The state of consciousness of patients after receiving methylphenidate. Timepoint: 12, 24, 36 and 48 hours after receiving the Methylphenidate. Method of measurement: Glasgow Coma Scale.
- Secondary Outcome Measures
Name Time Method The score obtained from the Reed Scaling criterion. Timepoint: 12, 24, 36, and 48 hours after receiving methylphenidate. Method of measurement: Levels 1 to 4 are obtained by examining blood pressure-respiratory-reflexes and pain response.